Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …

Simple Summary The monitoring of the minimal residual disease (MRD) in Chronic Myeloid
Leukemia is a key element in the management of affected patients because it reflects the …

Simple Summary Extracellular vesicles (EVs) are released by the majority of cell types and
can be isolated from both cell cultures and body fluids. They are involved in cell-to-cell …

Simple Summary This review discusses the optimal selection of BCR-ABL1 tyrosine kinase
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …

Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …

The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …

Background Due to its remarkable efficacy in producing hematologic, cytogenetic, and
molecular remissions, the FDA approved Imatinib as the first-line treatment for newly …

The success of personalized medicine depends on the discovery of biomarkers that allow
oncologists to identify patients that will benefit from a particular targeted drug. Molecular …

Introduction The therapeutic strategy and management of chronic myeloid leukemia (CML)
have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to …